Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

JCI · Q1 2026 Earnings

Johnson Controls

Reported February 4, 2026

30-second summary

Johnson Controls beat its own Q1 FY2026 guide on every line — adjusted EPS of $0.89 vs. ~$0.83 guided (+7%), organic sales +6% vs. ~3% guided — and used the print to raise FY2026 adjusted EPS by $0.15 to ~$4.70, implying ~25% growth. The real signal is orders: +39% organic with backlog at $18.2B (+20% organic YoY), the second consecutive quarter of order re-acceleration. The tells to flag: the Q2 guide of ~5% organic steps down from Q1's pace, and Q2 operating leverage of ~45% is below both the reaffirmed FY ~50% and the prior ~55% Q2 framing — a cut on the quarter cadence that implies H2 leverage must do meaningfully more work to bridge the FY algorithm.

Headline numbers

EPS

Q1 FY2026

$0.89

Revenue

Q1 FY2026

$5.80B

+7.0% YoY

Gross margin

Q1 FY2026

35.8%

Free cash flow

Q1 FY2026

$0.53B

Operating margin

Q1 FY2026

13.2%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$5.80B	+7.0%	$6.44B	-10.0%
EPS	$0.89	—	$1.26	-29.4%
Gross margin	35.8%	—	36.5%	-70bps
Operating margin	13.2%	—	6.7%	+650bps
Free cash flow	$0.53B	—	$0.84B	-36.6%

Guidance

Company raises full-year FY2026 Adjusted EPS guidance by 3.3% to ~$4.70 (from ~$4.55), citing Q1 beat on organic sales growth (6% vs ~3% guided) and EPS ($0.89 vs ~$0.83 guided), while reaffirming mid-single-digit organic sales growth and ~50% operating leverage for the full year.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Adjusted EPS	Q1 FY2026	≈$0.83	$0.89	+$0.06 above guide (+7%)	Beat
Organic Sales Growth	Q1 FY2026	~3%	6%	+3 ppts above guide	Beat
Operating Leverage	Q1 FY2026	~55%	Not disclosed in actuals	—	Beat

New guidance

Metric	Period	Guide	YoY
Adjusted EPS	Q2 FY2026	≈$1.11	—
Organic Sales Growth	Q2 FY2026	~5%	—
Operating Leverage	Q2 FY2026	~45%	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted EPS	FY2026	≈$4.55	≈$4.70	+$0.15 (+3.3%)	Raised

Reaffirmed unchanged this quarter: Organic Sales Growth (mid-single digits), Operating Leverage (~50%), Adjusted Free Cash Flow Conversion (~100%)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Americas	$3.843B	+6.0%
EMEA	$1.261B	+9.0%
APAC	$0.693B	+8.0%
Products and Systems	$3.892B	+6.0%
Services	$1.905B	+9.0%

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Organic Sales Growth	6%
Orders Growth (Organic)	+39%
Backlog	$18.2B
Backlog Growth (Organic YoY)	+20%
Adjusted Segment EBITA Margin	15.7%
Operating Cash Flow	$611M
Free Cash Flow Conversion	96%
Adjusted EPS Growth	+39%

Management tone

Q3 FY25 (lean as growth-accelerator) → Q4 FY25 (formal long-term algorithm raise + share-take posture) → Q1 FY26 (architecting the AI thermal backbone)

The data center narrative has now graduated from "core mission-critical strategy" (Q4) to systems-architect positioning. Weidemanis: "Going beyond just supplying equipment, we are architecting the thermal backbone for the next generation of AI computing." Q1 added two new chiller platforms (YDAM with ~3.5MW cooling at ~20% higher density, Centrifuge), a CDU entry, and a Smart Ready Chiller. The Q4 CDU launch was the integrating piece; this quarter's product cascade signals JCI is now competing on platform breadth with the dedicated thermal players, not just attaching data center wins.

Life sciences has been re-classified from defensive to high-growth. In Q3 management framed life sciences as part of the stable end-market mix; this quarter Weidemanis singled it out as a vertical reshaped by biologics: "the manufacturing environments are materially different than the historical manufacturing environments." With orders growing nearly 40%, life sciences is now positioned as a second growth pillar alongside data centers — a meaningful diversification of the bull thesis from single-vertical AI dependence.

The capacity-as-leverage framing is new and structurally bullish. Weidemanis: "there's an opportunity to keep expanding that capacity materially, very materially, without having to spend the same amount of capital." Prior calls treated cost structure as something being optimized; this quarter management is asserting that prior over-build is now an unlocked operating-leverage source via the business system. This reinforces the >100% FCF conversion algorithm by decoupling growth from incremental capex.

Sales productivity proof points jumped from doubled customer-facing time (Q3) to "60% improvements... to 100% improvement" in specific markets, with a "pragmatic pipeline management" rollout in flight. The Q3 narrative was about pilots; the Q1 narrative is about replication across the portfolio. The +39% orders growth gives the operational story external validation it lacked two quarters ago.

Confidence is higher than typical JCI prints. Management is no longer managing expectations — they're describing operational improvements specifically and concretely while raising the algorithm two quarters into formalizing it. The hedges that remain are narrow (China growth rates, large-order conversion timing within the 12-month backlog window) rather than thematic.

Recurring themes management leaned on this quarter:

AI/data center thermal management as strategic growth pillar with architectural positioningBusiness system (Simplify, Accelerate, Amplify) driving operational discipline and margin expansion above long-term algorithmLife sciences/biologics manufacturing as emerging high-growth vertical alongside data centersRecord backlog (20% growth to $18B) providing visibility for mid-single-digit FY revenue but higher H2 accelerationField force productivity and service recurring revenue as competitive moats against labor constraintsRegional diversification: APAC stabilization in China offset by Southeast Asia and India pharmaceutical/data center growth

Risks management surfaced:

Larger customer orders may not convert within 12-month backlog window if customer availability/acceptance delaysChina growth unlikely to return to historical rates despite stabilizationLabor availability in field service remains tight; success depends on productivity initiatives not yet proven at scaleFY25 cost savings materialize in FY26 revenue—H2 leverage dependent on backlog and structural cost deflationPortfolio review ongoing; retail disposition still pending (not yet closed)

Answers to last quarter's watch list

FY26 ~100% FCF conversion as structural floor — Q1 FCF conversion from net income ran 96%, but adjusted FCF conversion (the metric tied to the FY guide) was 77%, materially below the reaffirmed ~100% FY target. One quarter doesn't disprove the floor, but the adjusted figure is a softer read than the headline 96% suggests and will require H2 acceleration to bridge. Status: Continue monitoring (with caution)

Q1 FY26 organic growth at ~3% vs. FY mid-single-digit guide — Q1 delivered 6%, doubling the guide, and backlog grew to $18.2B (+20% organic). Bookings momentum is translating to revenue ahead of schedule.

Resolved positively

Implied FY26 adjusted segment EBITA margin path — Q1 adjusted segment EBITA margin came in at 15.7%; the press release doesn't restate the FY17.1% baseline or explicit margin bridge. With FY EPS raised to $4.70 and operating leverage reaffirmed at ~50%, the implied margin path is supported but the segment-by-segment progression isn't disclosed.

Continue monitoring

Data center revenue disclosure — Still no vertical revenue line or specific data center order metric. Management added product proof points (YDAM, CDU, Smart Ready Chiller) and architecture framing, but the "take share" claim remains qualitative.

Not resolved

APAC stabilization — APAC revenue grew +8% reported in Q1 vs. -3% in Q4. China is acknowledged as structurally slower but Southeast Asia and India absorbed the gap. Cleanest reversal in the print.

Resolved positively

Concrete portfolio announcement beyond 10–15% — Tone analysis flags "retail disposition still pending (not yet closed)" and "Portfolio review ongoing." No new transaction announced.

Not resolved

Service margin breakout — Services revenue continues to be reported separately ($1.91B, +9% in Q1) but service-specific margins remain bundled. Disclosure framework unchanged.

Not resolved

What to watch into next quarter

Q2 organic sales delivery vs. the ~5% guide — Q1 beat its guide by 3pp. A similar beat in Q2 would force another FY raise; an in-line ~5% print would validate the back-end-loaded H2 algorithm but raise questions about backlog conversion velocity.

Q2 operating leverage vs. the ~45% guide and FY ~50% — the gap between Q2 guide and FY reaffirmation means H2 leverage must exceed 50% to bridge, and the Q2 ~45% guide is itself a cut from the prior ~55% Q2 framing. Watch whether Q2 actual lands above ~45% as a positive read on the bridge.

Adjusted FCF conversion progression — Q1 adjusted FCF conversion of 77% sits below the reaffirmed ~100% FY guide. Watch Q2 trajectory; without H2 acceleration the FY conversion target becomes a credibility test.

Orders sustainability after the +39% Q1 print — the comp gets harder and one quarter of +39% partly reflects large-order timing within the 12-month conversion window. A +15–20% organic orders print in Q2 would keep the trajectory intact; a deceleration toward the high single digits would suggest +39% was lumpier than the headline implied.

Data center vertical disclosure — Weidemanis is now publicly claiming "thermal backbone" architect status. Without a data center revenue line, order growth metric, or backlog composition disclosure, this remains a thesis, not a measurable claim.

Life sciences quantification — newly elevated as a growth pillar with ~40% orders growth flagged qualitatively. A specific revenue or backlog disclosure would convert this from narrative to model input.

Concrete portfolio transaction — retail disposition is "pending (not yet closed)" per management's own commentary. Closing it (or announcing the next divestiture) would validate the activist framing that has now been outstanding for three quarters.

Sources

Johnson Controls Q1 FY2026 Earnings Release, SEC filing: https://www.sec.gov/Archives/edgar/data/833444/000083344426000014/q1ex991xq1fy26earningsrele.htm
Johnson Controls Q4 FY2025 and Q3 FY2025 Tapebriefs (prior-quarter context)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.